Movement Alert｜Guardant Health Inc. Falls 5.49% in Regular Trading, Litigation Costs and Ongoing Royalty Burden Overshadow Earnings Beat

Market Focus11-06

On November 6, Guardant Health Inc. fell 5.49% in Regular Trading, trading at $143.625, with turnover of $135 million.

The move followed a mix of better-than-expected quarterly results and a raised full-year revenue outlook, but sentiment remained pressured by patent litigation liabilities tied to duplex sequencing technology.

For the latest quarter, Guardant Health Inc. reported adjusted loss per share of $0.29 on revenue of $361 million, both ahead of market expectations, and lifted full-year revenue guidance to $1.36 billion-$1.37 billion. However, the company is still facing more than $245.2 million in damages, accrued royalties and interest, while also being required to pay a 6% royalty on covered product and service sales from June 1 until patent expiration in March 2033. That continuing cost overhang appears to have outweighed the earnings upside for investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment